Elevance Health, Inc. $ELV Shares Sold by Triodos Investment Management BV

Triodos Investment Management BV trimmed its stake in Elevance Health, Inc. (NYSE:ELV) by 11.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 81,380 shares of the company’s stock after selling 10,700 shares during the quarter. Elevance Health makes up 2.1% of Triodos Investment Management BV’s portfolio, making the stock its 21st biggest holding. Triodos Investment Management BV’s holdings in Elevance Health were worth $28,385,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in ELV. Forsta AP Fonden grew its position in shares of Elevance Health by 8.6% in the fourth quarter. Forsta AP Fonden now owns 95,220 shares of the company’s stock valued at $33,379,000 after purchasing an additional 7,520 shares during the period. Norges Bank purchased a new stake in shares of Elevance Health in the fourth quarter valued at $1,058,165,000. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Elevance Health in the fourth quarter valued at $65,906,000. Fideuram Asset Management Ireland dac purchased a new stake in Elevance Health during the fourth quarter valued at about $891,000. Finally, National Pension Service grew its position in Elevance Health by 5.5% during the fourth quarter. National Pension Service now owns 580,727 shares of the company’s stock valued at $203,574,000 after acquiring an additional 30,530 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Stock Performance

Shares of ELV stock opened at $394.40 on Friday. The business has a 50 day simple moving average of $343.75 and a 200 day simple moving average of $338.90. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The firm has a market capitalization of $85.65 billion, a price-to-earnings ratio of 16.78, a price-to-earnings-growth ratio of 2.22 and a beta of 0.66. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $408.00.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period last year, the company posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities research analysts anticipate that Elevance Health, Inc. will post 26.94 EPS for the current year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is presently 29.26%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ELV shares. The Goldman Sachs Group boosted their price target on Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Barclays boosted their price target on Elevance Health from $408.00 to $480.00 and gave the stock an “overweight” rating in a research note on Tuesday. UBS Group upped their price objective on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research note on Friday, May 22nd. Weiss Ratings raised Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, May 18th. Finally, Citigroup raised Elevance Health to a “buy” rating in a report on Wednesday, April 29th. Fourteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $403.11.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.